Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Autonomic dysfunction in multiple sclerosis.
Racosta JM, Kimpinski K, Morrow SA, Kremenchutzky M. Racosta JM, et al. Among authors: morrow sa. Auton Neurosci. 2015 Dec;193:1-6. doi: 10.1016/j.autneu.2015.06.001. Epub 2015 Jun 7. Auton Neurosci. 2015. PMID: 26070809 Review.
Regional reduction in cortical blood flow among cognitively impaired adults with relapsing-remitting multiple sclerosis patients.
Hojjat SP, Cantrell CG, Vitorino R, Feinstein A, Shirzadi Z, MacIntosh BJ, Crane DE, Zhang L, Morrow SA, Lee L, O'Connor P, Carroll TJ, Aviv RI. Hojjat SP, et al. Among authors: morrow sa. Mult Scler. 2016 Oct;22(11):1421-1428. doi: 10.1177/1352458515622696. Epub 2016 Jan 11. Mult Scler. 2016. PMID: 26754799 Free PMC article.
Normal appearing white matter permeability: a marker of inflammation and information processing speed deficit among relapsing remitting multiple sclerosis patients.
Eftekhari E, Hojjat SP, Vitorino R, Carroll TJ, Cantrell CG, Lee L, Taylor MW, Morrow SA, Benhabib H, Aviv RI, Kassner A. Eftekhari E, et al. Among authors: morrow sa. Neuroradiology. 2017 Aug;59(8):771-780. doi: 10.1007/s00234-017-1862-7. Epub 2017 Jun 16. Neuroradiology. 2017. PMID: 28623483
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators. Kapoor R, et al. Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12. Lancet Neurol. 2018. PMID: 29545067 Clinical Trial.
178 results